Horizon Discovery Share Discussion Threads

[blueball] 14/4/2014 13:50

I'm out for a loss pity its a great co.

[mirabeau] 14/4/2014 10:59

Sold. I simply cannot afford to be in a stock that's quite obviously continuing to weaken. Took a grand loss or more

HZD's a great company so will return when IPO sellers have shot their load

GLA

[hydrus] 14/4/2014 09:41

Interesting company but I fear the trend in biotech stocks could hit this heavily. It is very expensive although some promise if course.

[blueball] 14/4/2014 08:33

Marked down this am.

[manics] 10/4/2014 17:50

Biotech taking another smackdown in the US tonight.

[malhashemi] 10/4/2014 15:41

Sitting on a small loss too .. Don't think that down drift is stock specific .. Just apathy in the market hitting bio stocks in general

[cestnous] 10/4/2014 14:08

Et moi aussi Mira. Patience needed here.

[mirabeau] 10/4/2014 13:38

Sat on a loss now but i'm confident in my choice of stock. This is a world class company with leading technology. Price weakness due to some IPO holders reducing their exposure, obviously

If it's good enough for Astra-Zeneca then it's good enuff for moi

[blueball] 10/4/2014 13:32

Sub 200p today.

[mikeja] 08/4/2014 21:31

Thanks for your posts,Mirabeau,very useful

[mirabeau] 07/4/2014 18:43

Monday, 07 April 2014 08:37 Tony Quested

Horizon opens up a new world of research capability

Horizon Discovery has broadened its technology range to give life scientists a broader base of research tools.

The personalised medicines pioneer has launched its full range of GENASSIST™ gene editing kits, reagents and support services that enable easier, robust implementation of gene editing experiments with CRISPR and rAAV.

GENASSIST offers a broad range of thoroughly validated tools alongside a suite of services designed to enable any cell line generation project to be efficiently addressed.

The company has designed GENASSIST to make genome editing accessible for everyone.

Horizon offers not just plasmids for CRISPR gene editing but also custom guide RNA design and validation (to provide customers with confidence that they are working with a suitably active guide); custom donor design and manufacturing; QuickStart cell lines that constitutively produce Cas9 nickase; over 550 X-MAN™ cell lines ready for further modification; and direct access to Horizon's expert gene-editing scientists.

By taking a technology agnostic approach that employs both CRISPR and rAAV gene editing technologies, Horizon is able to not only work with researchers to suggest the right approach for their specific project needs, but also is in the unique position of being able to combine the technologies to achieve efficiencies not possible with one technology alone.

Eric Rhodes, VP of R & D and chief technology officer for Horizon, said: "Horizon's success has been driven by the way we partner with our customers. By offering access to our gene editing expertise we give researchers the best chance of success in their gene editing projects.

"Our new GENASSIST range of tools and services, combined with access to rAAV, ZFN, and CRISPR technologies, gives researchers an invaluable resource to determine the function of endogenous gene alterations and their effect on disease and therapeutic responses."

Horizon Discovery CEO, Dr Darrin Disley, added: "Horizon's goal is to make the latest developments in gene editing accessible to the wider scientific audience.

"As the only company which can offer both nuclease techniques in the form of CRISPR or ZFN and homologous recombination harnessing rAAV, we are ensuring that researchers can make an informed choice of which technology or combination of technologies is best in order to gain the answer to the biological question being asked."

[mirabeau] 07/4/2014 13:04

Mr D

I suspect they'll restrict their RNS's to revenue generating events (commercial deals, collaborations) rather than product offerings etc

Cheers

M

[mr dexy] 07/4/2014 11:43

M,

Not worthy of an RNS?

Regards


Mr D

[mirabeau] 07/4/2014 09:51

07/04/2014

Horizon Discovery Launches New GENASSIST CRISPR and rAAV Gene Editing Tools and Services

Comprehensive product and service solution enables easier, robust implementation of gene editing experiments in customer's hands

Cambridge, UK, 07 April 2014: Horizon Discovery™ Group plc (LSE: HZD) (Horizon), the life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announced the launch of its full range of GENASSIST™ gene editing kits, reagents and support services that enable easier, robust implementation of gene editing experiments with CRISPR and rAAV. GENASSIST offers a broad range of thoroughly validated tools alongside a suite of services designed to enable any cell line generation project to be efficiently addressed.

The company has designed GENASSIST (www.horizondiscovery.com/GENASSIST) to make genome editing accessible for everyone. Horizon offers not just plasmids for CRISPR gene editing, but also custom guide RNA design and validation (to provide customers with confidence that they are working with a suitably active guide); custom donor design and manufacturing; QuickStart cell lines that constitutively produce Cas9 nickase; over 550 X-MAN™ cell lines ready for further modification; and direct access to Horizon's expert gene-editing scientists.

By taking a technology agnostic approach that employs both CRISPR and rAAV gene editing technologies, Horizon is able to not only work with researchers to suggest the right approach for their specific project needs, but is also in the unique position of being able to combine the technologies to achieve efficiencies not possible with one technology alone.

"Horizon's success has been driven by the way we partner with our customers. By offering access to our gene editing expertise we give researchers the best chance of success in their gene editing projects," said Eric Rhodes, VP of R&D and Chief Technology Officer, Horizon Discovery. "Our new GENASSIST range of tools and services, combined with access to rAAV, ZFN, and CRISPR technologies, gives researchers an invaluable resource to determine the function of endogenous gene alterations and their effect on disease and therapeutic responses."

Dr Darrin M Disley, CEO, Horizon Discovery, commented: "Horizon's goal is to make the latest developments in gene editing accessible to the wider scientific audience. As the only company which can offer both nuclease techniques in the form of CRISPR or ZFN and homologous recombination harnessing rAAV, we are ensuring that researchers can make an informed choice of which technology or combination of technologies is best in order to gain the answer to the biological question being asked."

[blueball] 06/4/2014 20:10

Tomorrow take a look at XLM a new IPO could add 20% on opening..dont worry HZD will be fine in a months time.

[manics] 06/4/2014 08:13

Looking at HZD still and have cash now ready. Nasdaq sell off on Friday (a day two continuation) has me thinking certain sectors might be in for some chop in the immediate term -which could include BioTech.

Certainly a sudden US caution around Tech & BioTech IPO's.

[blueball] 04/4/2014 13:34

Another top up for me of 1500 shares.

always good to buy on a quiet day.

Crispen Odeys fund holds 3% of company a good sign.

[blueball] 04/4/2014 09:00

hxxp://www.horizondiscovery.com/about-us/our-company/news-event/22/2014%20american%20association%20of%20cancer%20research%20annual%20meeting

[mirabeau] 03/4/2014 18:13

Thursday, 03 April 2014 13:11 Tony Quested

Recruitment drive in full swing at Horizon Discovery

CEO Darrin Disley says staff morale is running at "an all-time high" at Horizon Discovery following the rollout of the biotech company's post-IPO incentive plans and roadmap for expansion.

Dr Disley said that a week on from the highly successful AIM IPO a recruitment drive was in full swing with an open application phase for all scientific and commercial divisions in play.

Around a dozen positions are currently being advertised on the company's website – hxxp://www.horizondiscovery.com/about-us/our-company/careers .

The gene editing market leader is targeting a global $48bn market and is set to double the size of its Cambridge Research Park headquarters. The success of the IPo underlined the current appetite of investors for a slice of the high-end medical technology company shares.

The placing by Panmure Gordon (UK) Limited, raised £68.6m from institutional investors comprising £40m for the company before expenses and the sale of £28.6m of sale shares. As Business Weekly exclusively revealed this was almost seven times oversubscribed and a record high for a Cambridge biotech on AIM: It is also in the top five largest IPOs ever by a non-therapeutic UK biotech.

The group has a broad international customer base including pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centres around the world.

2013 revenues were derived from 353 unique customers including AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, Merck & Co., Novartis Institute of Biomedical Research and Takeda.

Horizon's proprietary translational genomics platform, GENESIS™ – comprising three gene-editing tools: rAAV (under exclusive licence), ZFN (under non-exclusive licence) and CRISPR (under non-exclusive licence) – offers a precise and flexible gene-editing solution.

The group operates a powerful business model, differentiated from typical biotechnology companies, where it can leverage both internally-funded and customer-funded cell line development, drug discovery services and cell line and derivative reagent product offerings.

Additional leverage is achieved by combining the offering with novel IP, oncology and drug discovery expertise allowing the Group to accrue downstream milestones and the potential for product royalties.

Horizon supplies its services and products into multiple markets, including the translational genomics research market; the cell based assays market; the molecular diagnostics market; and the bioproduction market. Combined, the directors estimate these markets to total more than £29 billion ($48bn) by 2015.

Horizon plans to use the cash to broaden its product portfolio and service offering as well for aggressive territorial expansion globally.

[twitterman] 03/4/2014 11:23

Haha thats some news for you. Will have a good read through.

Cast you eye over CTP also. Directors bought £500k in shares recently. No debt, £5m in cash and on the aquisition trail. Worth looking at Ian smith background also. He is a serial entrepenuer like david breith at coms.

[mirabeau] 03/4/2014 11:20

twitterman

You want news? Here's some news for you that will all provide significant benefits to Horizon in the coming months and years. And I bet this is the only the start:--


24/03/2014
Horizon Discovery Group plc Raises £68.6 million
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM... (more)

27/02/2014
Horizon Discovery Group plc Announces Intention to Float
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM... (more)

17/02/2014
Horizon Discovery Signs Supply and Distribution Agreement with Sirion Biotech GmbH
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to... (more)

12/02/2014
Horizon Discovery Signs Distribution Agreement with Haplogen
Horizon will market and distribute haploid gene trap mutant collection to its global... (more)

10/02/2014
Horizon Discovery Launches GENASSIST Line of Kits and Reagents for Gene-Editing, utilizing CRISPR Technology
New CRISPR-ready cell line kit and validated RNA guide service to enable easier,... (more)

30/01/2014
Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan
Agreement covers use of 250 of Horizon's X-MAN genetically defined isogenic... (more)

16/01/2014
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic Tests
Transgenomic will use Horizon's genetically defined reference standards in... (more)

14/01/2014
Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
Cambridge, UK, 14 January 2014: Horizon Discovery (Horizon), a leading provider of... (more)

07/01/2014
Horizon Discovery Announces Oncology Research, Collaboration and License Agreement with AstraZeneca
Cambridge, UK, 07 January 2014: Horizon Discovery (Horizon) and AstraZeneca have... (more)



17/12/2013
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon's GENESIS suite of gene editing technologies Cambridge,... (more)

22/11/2013
Horizon Discovery and AstraZeneca win "Licensing Deal of the Year" at Scrip Awards 2013
Cambridge, UK, 22 November 2013: Horizon Discovery (Horizon) has won "Licensing... (more)

21/11/2013
Horizon Discovery CEO Joins UKTI Delegation to India Led by David Cameron
Senior business and political leaders from India and Europe meet at Prabodhan Leaders'... (more)

18/11/2013
Horizon Discovery Highest Ranked Biotechnology Company in the UK in the 2013 Deloitte Technology Fast 50
Horizon attributes its 1027% per cent Revenue Growth to a strong product portfolio,... (more)

23/10/2013
David Evans Steps Down as Chairman of the Board for Horizon Discovery
Cambridge, UK, 23 October 2013: Horizon Discovery (Horizon), a leading provider of... (more)

17/10/2013
Horizon Discovery Selected for Tech City UK's 'Future Fifty' Program
Fast track program selects first cohort of 25 high-growth businesses to help accelerate... (more)

15/10/2013
Horizon Discovery receives share of €5.75M ($7.8M) EU FP7 Grant
Grant will fund projects investigating genomic variants affecting coronary artery... (more)

08/10/2013
Horizon Discovery and Blueprint Medicines Enter Oncology Research Service Agreement
Horizon Discovery and Blueprint Medicines Enter Oncology Research Service Agreement Horizon... (more)

16/09/2013
Horizon Discovery Licenses CRISPR Gene-Editing Technology from Harvard University
Gene-editing platform now includes rAAV, ZFN and CRISPR Cambridge, UK, 16... (more)

03/09/2013
Horizon Discovery licenses Zinc finger nuclease gene editing technology from Sigma-Aldrich
Horizon to utilize both nuclease and rAAV gene editing platforms in custom cell-line... (more)

01/08/2013
Horizon Discovery Strengthens Board with Appointment of Dr. Ian Gilham
Horizon Discovery Strengthens Board with Appointment of Dr. Ian Gilham Cambridge,... (more)

16/07/2013
Horizon Discovery and RIKEN GENESIS Sign Distribution Agreement
Horizon Discovery and RIKEN GENESIS Sign Distribution Agreement Agreement covers... (more)

18/06/2013
Horizon Discovery and Hisun Pharmaceuticals Partner on Gene-Engineered Bioproduction Cell Line
Precisely engineered CHO cell line will enable faster, more efficient development... (more)

03/06/2013
Horizon Discovery Announces £6.9 Million ($10.5 Million) Series C Continuation Fundraising
Horizon Discovery Announces £6.9 Million ($10.5 Million) Series C Continuation... (more)

22/04/2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca
Cambridge, UK, 22 April 2013: Horizon Discovery (Horizon) and AstraZeneca have entered... (more)

15/04/2013
Horizon Discovery and Diatech Pharmacogenetics Sign Distribution Agreement
Agreement covers distribution of Horizon Diagnostics' molecular reference standards... (more)

03/04/2013
Crown Bioscience, Inc. and Horizon Discovery Announce Exclusive Two Year Agreement to Offer Combined Solutions for In Vivo Drug Discovery Model Development
Santa Clara, CA and Cambridge, UK (April 3rd 2013) – Crown Bioscience, Inc.... (more)

05/03/2013
Horizon Introduces Quantitative Multiplex Genomic Reference Standards for Tumor Profiling
Increasing the precision and utility of molecular assays for cancer genotype screening Cambridge,... (more)

04/03/2013
Horizon Discovery Establishes Three New Centers of Excellence in Asia
Centers will apply Horizon's rAAV gene editing technology to a range of oncology... (more)

11/02/2013
Horizon Discovery Wins Most Promising Company at World Conference on Personalized Medicine
Award based on technology, performance to date, and forward plans Cambridge and... (more)

14/01/2013
Horizon Discovery and Boehringer Ingelheim Enter Oncology Research Service Collaboration
Five-year collaboration will support Boehringer Ingelheim's drug discovery... (more)

[blueball] 03/4/2014 10:37

Manics you can buy 1500 shares with no problem.